降圧剤の世界市場レポート 2025年

降圧剤市場規模は、今後数年間でわずかな成長が見込まれます。2029年には年間平均成長率（CAGR）1.9％で404億1,000万米ドルに成長します。予測期間中の成長は、費用対効果と価格、新たな治療イノベーション、疫学動向、規制の変更と承認、高齢化のダイナミクス、ヘルスケア政策と償還の変更に起因すると考えられます。予測期間における主な動向には、治療イノベーション、疫学的変化、規制状況、ヘルスケア政策、診断とモニタリングの進歩などが含まれます。

座りがちなライフスタイルは降圧剤市場の成長に大きく寄与しています。ジャンクフードの消費、健康的でバランスの取れた食事の不足、不規則な勤務シフトによる睡眠不足などの要因が、高血圧の増加につながっています。高血圧は、心臓病による死亡の少なくとも45％、脳卒中による死亡の51％の主な原因となっています。高血圧と診断されると、患者はその重症度に応じて薬を服用して状態を管理しなければならないです。例えば、2023年5月、イングランドの政府部門である国民保健サービス（National Health Service）は、高血圧の有病率は年齢とともに上昇し、16歳から44歳の成人では9％から始まり、65歳以上では60％まで増加すると報告しました。この動向は降圧剤に対する持続的な需要を生み出し、市場成長の重要な促進要因となっています。

心血管疾患の有病率の上昇は、降圧剤市場の今後の成長を牽引すると予想されます。心血管疾患には、心臓や血管に影響を及ぼすさまざまな疾患が含まれ、喫煙、高血圧、高コレステロール、糖尿病、肥満、座りがちなライフスタイルなどが危険因子として挙げられます。降圧剤は、高齢者における心血管疾患の主要な危険因子である高血圧を管理し、緩和する上で重要な役割を果たします。2022年10月、国立医学図書館は、2035年までに米国人口の45.1％が心血管疾患に罹患する可能性があり、その総費用は1兆1,000億米ドルに達すると予測しました。さらに、2023年5月の世界心臓連盟のデータでは、2021年の心血管疾患による死亡者数は2050万人でした。その結果、心血管疾患の有病率の増加が降圧剤市場の拡大を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界降圧剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の降圧剤市場：成長率分析
• 世界の降圧剤市場の実績：規模と成長, 2019-2024
• 世界の降圧剤市場の予測：規模と成長, 2024-2029, 2034F
• 世界降圧剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の降圧剤市場セラピューティクス、実績と予測, 2019-2024, 2024-2029F, 2034F
• 利尿剤
• アンジオテンシン受容体拮抗薬（ARB）
• アンジオテンシン変換酵素（ACE）阻害剤
• ベータ遮断薬
• アルファ遮断薬
• カルシウムチャネル遮断薬
• レニン阻害剤
• 血管拡張薬
• 世界の降圧剤市場病気の原因別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 原発性高血圧
• 二次性高血圧
• 世界の降圧剤市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア
• 世界の降圧剤市場利尿薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チアジド系利尿薬
• ループ利尿薬
• カリウム保持性利尿薬
• 世界の降圧剤市場アンジオテンシン受容体拮抗薬（ARB）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロサルタン
• バルサルタン
• イルベサルタン
• カンデサルタン
• 世界の降圧剤市場、ベータ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• メトプロロール
• アテノロール
• カルベジロール
• ビソプロロール
• 世界の降圧剤市場、アルファ遮断薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキサゾシン
• プラゾシン
• テラゾシン
• 世界の降圧剤市場カルシウムチャネル遮断薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アムロジピン
• ジルチアゼム
• ベラパミル
• ニフェジピン
• 世界の降圧剤市場レニン阻害剤の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アリスキレン
• 世界の降圧剤市場血管拡張薬の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒドララジン
• ミノキシジル

第7章 地域別・国別分析

• 世界の降圧剤市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の降圧剤市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 降圧剤市場：競合情勢
• 降圧剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbiVe Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis AG
• Sanofi SA
• Astra Zeneca plc
• Abbott Laboratories
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• C.H. Boehringer Sohn AG & Ko. KG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Daiichi Sankyo Company Limited
• Fresenius Kabi AG
• Sun Pharmaceuticals LLC
• Cipla Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 降圧剤市場2029：新たな機会を提供する国
• 降圧剤市場2029：新たな機会を提供するセグメント
• 降圧剤市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anti-hypertensive drugs constitute a category of medications utilized in the treatment of high blood pressure (hypertension). The primary objective of antihypertensive therapy is to prevent the adverse effects associated with elevated blood pressure, such as myocardial infarction and stroke.

The key therapeutic classes of anti-hypertensive drugs include diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, commonly known as water pills, work by increasing the elimination of water and salt from the body through urine. Various sources of hypertension encompass primary and secondary hypertension, both of which are addressed through treatment modalities in hospitals, clinics, and home care settings.

The anti-hypertensive drugs market research report is one of a series of new reports from The Business Research Company that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-hypertensive drugs market size has grown steadily in recent years. It will grow from $36.66 billion in 2024 to $37.5 billion in 2025 at a compound annual growth rate (CAGR) of 2.3%. The growth in the historic period can be attributed to environmental and lifestyle influences, historical market competition, historical treatment preferences, economic conditions, historical global health trends.

The anti-hypertensive drugs market size is expected to see marginal growth in the next few years. It will grow to $40.41 billion in 2029 at a compound annual growth rate (CAGR) of 1.9%. The growth in the forecast period can be attributed to cost-effectiveness and affordability, emerging therapeutic innovations, epidemiological trends, regulatory changes and approvals, aging population dynamics, healthcare policies and reimbursement changes. Major trends in the forecast period include therapeutic innovation, epidemiological shifts, regulatory landscape, healthcare policies, advancements in diagnosis and monitoring.

A sedentary lifestyle significantly contributes to the growth of the anti-hypertensive drug market. Factors such as the consumption of junk food, an inadequate healthy and balanced diet, and insufficient sleep due to irregular work shifts have led to an increase in hypertension. Hypertension is a primary cause of at least 45% of deaths from heart disease and 51% of deaths from stroke. Once diagnosed with hypertension, patients must take medication to manage their condition, depending on its severity. For instance, in May 2023, the National Health Service, a government department in England, reported that the prevalence of hypertension rises with age, starting at 9% among adults aged 16 to 44 and increasing to 60% for those aged 65 and older. This trend creates a sustained demand for anti-hypertensive products, acting as a key driver for the market's growth.

The escalating prevalence of cardiovascular diseases is expected to drive future growth in the anti-hypertensive drugs market. Cardiovascular diseases encompass a range of conditions affecting the heart and blood vessels, with risk factors including smoking, high blood pressure, high cholesterol, diabetes, obesity, and a sedentary lifestyle. Anti-hypertensive drugs play a crucial role in managing and mitigating high blood pressure, a major risk factor for cardiovascular diseases in older adults. In October 2022, the National Library of Medicine projected that by 2035, 45.1% of the US population could have cardiovascular disease, with total costs reaching $1.1 trillion. Additionally, data from the World Heart Federation in May 2023 revealed 20.5 million deaths from cardiovascular diseases in 2021. Consequently, the increasing prevalence of cardiovascular diseases is propelling the expansion of the anti-hypertensive drugs market.

Prominent companies in the anti-hypertensive drugs market are concentrating their efforts on introducing innovative products, including Metoprolol Succinate Extended-Release Tablets, to gain a competitive advantage. Metoprolol Succinate Extended-Release Tablets serve as anti-hypertensive drugs tailored for patients with hypertension. For example, in June 2023, Granules India Limited, a pharmaceutical manufacturing company based in India, unveiled Metoprolol Succinate Extended-Release Tablets, which received approval from the US Food and Drug Administration (FDA). These tablets, available in strengths ranging from 25mg to 200mg, function as beta-blockers, slowing down the heart rate, easing the workload on the heart, and ultimately lowering blood pressure.

Major companies in the anti-hypertensive drugs market are concentrating on obtaining regulatory approvals to broaden their product portfolios and improve their competitiveness in the market. Regulatory approvals are the official permissions granted by government agencies that oversee the safety and efficacy of pharmaceutical products before they can be marketed and sold to consumers. For example, in March 2024, Idorsia Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for its new medication, aprocitentan, branded as Tryvio. This drug is specifically intended to treat resistant hypertension in adults whose condition is not sufficiently managed by other antihypertensive medications. Aprocitentan is significant as it is the first endothelin receptor antagonist approved for this indication, representing a new therapeutic approach in the treatment of hypertension.

The US Food and Drug Administration (FDA) has issued guidance regarding the development of fixed-combination drugs for hypertension. This guidance primarily focuses on the clinical development of two-drug combinations comprising previously approved products. The FDA anticipates a decrease in adverse effects for combinations that include doses below each drug's maximum dose compared to single drug regimens at their maximum dose. Current medical guidelines recommend initiating patients on two drugs at less than their full doses, marking a departure from the earlier practice of starting with a single drug and titrating up to the maximum dose before introducing additional drugs. This guidance is expected to regulate the development of fixed-combination drugs for hypertension.

Major companies operating in the anti-hypertensive drugs market include Pfizer Inc., Johnson & Johnson Ltd., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbiVe Inc., Bayer AG, Novartis AG, Sanofi SA, Astra Zeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, C.H. Boehringer Sohn AG & Ko. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Company Limited, Fresenius Kabi AG, Sun Pharmaceuticals LLC, Cipla Limited, Dr. Reddy's Laboratories, Hikma Pharmaceuticals PLC, Lupin Limited, Torrent Pharmaceuticals Ltd, Noden Pharma DAC, Actelion Pharmaceuticals Ltd.

North America was the largest region in the anti-hypertensive drugs market in 2024. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the anti-hypertensive drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Hypertensive Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-hypertensive drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-hypertensive drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-hypertensive drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Diuretics; Angiotensin Receptor Blockers (ARBs); Angiotensin Converting Enzyme (ACE) Inhibitors; Beta Blockers; Alpha Blockers; Calcium Channel Blockers; Renin Inhibitors; Vasodilators
• 2) By Disease Source: Primary Hypertension; Secondary Hypertension
• 3) By End Users: Hospitals; Clinics; Homecare
• Subsegments:
• 1) By Diuretics: Thiazide Diuretics; Loop Diuretics; Potassium-Sparing Diuretics
• 2) By Angiotensin Receptor Blockers (ARBs): Losartan; Valsartan; Irbesartan; Candesartan
• 3) By Angiotensin Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril; Benazepril
• 4) By Beta Blockers: Metoprolol; Atenolol; Carvedilol; Bisoprolol
• 5) By Alpha Blockers: Doxazosin; Prazosin; Terazosin
• 6) By Calcium Channel Blockers: Amlodipine; Diltiazem; Verapamil; Nifedipine
• 7) By Renin Inhibitors: Aliskiren
• 8) By Vasodilators: Hydralazine; Minoxidil
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson Ltd.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; AbbiVe Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anti-Hypertensive Drugs Market Characteristics

3. Anti-Hypertensive Drugs Market Trends And Strategies

4. Anti-Hypertensive Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anti-Hypertensive Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anti-Hypertensive Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anti-Hypertensive Drugs Market Growth Rate Analysis
• 5.4. Global Anti-Hypertensive Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anti-Hypertensive Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anti-Hypertensive Drugs Total Addressable Market (TAM)

6. Anti-Hypertensive Drugs Market Segmentation

• 6.1. Global Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diuretics
• Angiotensin Receptor Blockers (ARBs)
• Angiotensin Converting Enzyme (ACE) Inhibitors
• Beta Blockers
• Alpha Blockers
• Calcium Channel Blockers
• Renin Inhibitors
• Vasodilators
• 6.2. Global Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Hypertension
• Secondary Hypertension
• 6.3. Global Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Homecare
• 6.4. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Diuretics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thiazide Diuretics
• Loop Diuretics
• Potassium-Sparing Diuretics
• 6.5. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Angiotensin Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Losartan
• Valsartan
• Irbesartan
• Candesartan
• 6.6. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Beta Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Metoprolol
• Atenolol
• Carvedilol
• Bisoprolol
• 6.7. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Alpha Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxazosin
• Prazosin
• Terazosin
• 6.8. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amlodipine
• Diltiazem
• Verapamil
• Nifedipine
• 6.9. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Renin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aliskiren
• 6.10. Global Anti-Hypertensive Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydralazine
• Minoxidil

7. Anti-Hypertensive Drugs Market Regional And Country Analysis

• 7.1. Global Anti-Hypertensive Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anti-Hypertensive Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Hypertensive Drugs Market

• 8.1. Asia-Pacific Anti-Hypertensive Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Hypertensive Drugs Market

• 9.1. China Anti-Hypertensive Drugs Market Overview
• 9.2. China Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Hypertensive Drugs Market

• 10.1. India Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Hypertensive Drugs Market

• 11.1. Japan Anti-Hypertensive Drugs Market Overview
• 11.2. Japan Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Hypertensive Drugs Market

• 12.1. Australia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Hypertensive Drugs Market

• 13.1. Indonesia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Hypertensive Drugs Market

• 14.1. South Korea Anti-Hypertensive Drugs Market Overview
• 14.2. South Korea Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Hypertensive Drugs Market

• 15.1. Western Europe Anti-Hypertensive Drugs Market Overview
• 15.2. Western Europe Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Hypertensive Drugs Market

• 16.1. UK Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Hypertensive Drugs Market

• 17.1. Germany Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Hypertensive Drugs Market

• 18.1. France Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Hypertensive Drugs Market

• 19.1. Italy Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Hypertensive Drugs Market

• 20.1. Spain Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Hypertensive Drugs Market

• 21.1. Eastern Europe Anti-Hypertensive Drugs Market Overview
• 21.2. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Hypertensive Drugs Market

• 22.1. Russia Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Hypertensive Drugs Market

• 23.1. North America Anti-Hypertensive Drugs Market Overview
• 23.2. North America Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Hypertensive Drugs Market

• 24.1. USA Anti-Hypertensive Drugs Market Overview
• 24.2. USA Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Hypertensive Drugs Market

• 25.1. Canada Anti-Hypertensive Drugs Market Overview
• 25.2. Canada Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Hypertensive Drugs Market

• 26.1. South America Anti-Hypertensive Drugs Market Overview
• 26.2. South America Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Hypertensive Drugs Market

• 27.1. Brazil Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Hypertensive Drugs Market

• 28.1. Middle East Anti-Hypertensive Drugs Market Overview
• 28.2. Middle East Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Hypertensive Drugs Market

• 29.1. Africa Anti-Hypertensive Drugs Market Overview
• 29.2. Africa Anti-Hypertensive Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anti-Hypertensive Drugs Market, Segmentation By Disease Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anti-Hypertensive Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Hypertensive Drugs Market Competitive Landscape And Company Profiles

• 30.1. Anti-Hypertensive Drugs Market Competitive Landscape
• 30.2. Anti-Hypertensive Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbiVe Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Hypertensive Drugs Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis AG
• 31.3. Sanofi SA
• 31.4. Astra Zeneca plc
• 31.5. Abbott Laboratories
• 31.6. GlaxoSmithKline plc
• 31.7. Takeda Pharmaceutical Company Limited
• 31.8. Eli Lilly and Company
• 31.9. C.H. Boehringer Sohn AG & Ko. KG
• 31.10. Teva Pharmaceutical Industries Ltd.
• 31.11. Mylan N.V.
• 31.12. Daiichi Sankyo Company Limited
• 31.13. Fresenius Kabi AG
• 31.14. Sun Pharmaceuticals LLC
• 31.15. Cipla Limited

32. Global Anti-Hypertensive Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Hypertensive Drugs Market

34. Recent Developments In The Anti-Hypertensive Drugs Market

35. Anti-Hypertensive Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Anti-Hypertensive Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anti-Hypertensive Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anti-Hypertensive Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer